Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 136 clinical trials
None
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive HR-Positive Metastatic Breast Cancer

HR+/HER2+Human epidermal growth factor receptor 2 positive and hormone receptor positivemetastatic breast cancer is a special subtype of HER2+breast cancer. Conventional guidelines recommend

growth factor
estrogen receptor
estrogen
immunological adjuvant
HER2
  • 9 views
  • 27 Jan, 2021
  • 2 locations
None
Assessing the Immunogenicity of pING-hHER3FL

protein and will be used in a phase I study as immunotherapeutic agent to target cancers that are known to express the human epidermal growth factor receptor HER3. The human epidermal growth factor

metastasis
EGFR
liver metastasis
metastatic solid tumor
HER2
  • 0 views
  • 24 Sep, 2021
  • 1 location
None
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive human epidermal growth factor receptor 2

neutrophil count
targeted therapy
growth factor
immunostimulant
HER2
  • 18 views
  • 08 Sep, 2021
  • 2 locations
None
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The

growth factor
estrogen receptor
estrogen
immunological adjuvant
liver metastasis
  • 0 views
  • 30 Nov, 2021
  • 19 locations
None
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing

neutrophil count
growth factor
estrogen
immunohistochemistry
ejection fraction
  • 107 views
  • 12 Dec, 2021
  • 5 locations
None
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2

growth factor
HER2
breast cancer
hormone therapy
tumor cells
  • 5 views
  • 25 Nov, 2021
  • 1 location
None
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR

EGFR
growth factor
epidermal growth factor receptor
erbb2
her2/neu-negative breast cancer
  • 0 views
  • 04 Jul, 2021
  • 1 location
None
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the

invasive breast cancer
capecitabine
growth factor
mammogram
immunohistochemistry
  • 47 views
  • 19 Dec, 2021
  • 13 locations
None
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor

cancer treatment
EGFR
measurable disease
HER2
growth factor
  • 8 views
  • 26 Dec, 2021
  • 32 locations
None
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase

neutrophil count
tamoxifen
abemaciclib
growth factor
cish
  • 4 views
  • 28 Jan, 2021
  • 13 locations